Myeloma Drug Linked to Early Cytokine Release Events
Adults treated with linvoseltamab face potential side effects shortly after beginning the medication's dosing schedule.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should patients receiving complex cancer immunotherapies undergo longer hospital observation periods?
Recent findings show that cytokine release syndrome, a common inflammatory response, occurs most frequently within 6 to 8 hours after the first step-up dose of the multiple myeloma drug linvoseltamab. The FDA granted accelerated approval for the medication in July 2025 for adults with relapsed or refractory disease.
Why it matters
Understanding the timing of this immune response is critical for patient safety, as it dictates the necessity of mandatory inpatient monitoring during the initial stages of treatment. Recognizing these patterns helps patients and clinicians prepare for potential clinical intervention if symptoms emerge.
An analysis of 117 patients receiving a 200-mg regimen of linvoseltamab found that cytokine release syndrome occurred in 26.5% of individuals after the first dose, 13.3% after the second, and 2.7% after the first full dose. Almost all reported events were grade 1 or 2 in severity.
The players
FDA
The United States regulatory agency responsible for evaluating the safety and efficacy of new medical therapies.
The details
Linvoseltamab requires a specific step-up dosing schedule—5 mg on day 1, 25 mg on day 8, and the first full 200-mg dose on day 15—to help the immune system acclimate to the therapy. Because the drug can trigger a rapid inflammatory response, prescribing information mandates a 24-hour hospital stay after the first and second step-up doses. During the analysis, 18.8% of patients required tocilizumab to manage symptoms, while one participant needed vasopressor support.
Timeline
July 2025: The FDA granted accelerated approval for linvoseltamab.
Day 1: Patients received the initial 5 mg dose.
Day 8: Patients received the second 25 mg dose.
Day 15: Patients received the first full 200-mg dose.
Health Landscape
This analysis presented at the International Myeloma Society Annual Meeting clarifies clinical expectations for managing immunotherapy side effects in multiple myeloma patients. It highlights the importance of standardized monitoring protocols to improve the safety profile of emerging biological therapies.
If you are prescribed linvoseltamab, you and your care team should plan for mandatory 24-hour hospital stays following your initial step-up doses to monitor for symptoms. Be prepared to discuss potential early-intervention strategies with your doctor if you have concerns about inflammatory side effects.
The takeaway
The risk of cytokine release syndrome is highest shortly after starting linvoseltamab, but it decreases significantly as you progress to the full dose. Tracking your physical comfort in the 6 to 8 hours following every administration is a proactive habit worth discussing with your oncology team.
Further reading
For broader information on current oncology treatment protocols, visit the Cancer section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should patients receiving complex cancer immunotherapies undergo longer hospital observation periods?
